期刊文献+

单剂量加替沙星口服在Beagle犬体内药代动力学研究 被引量:4

Pharmacokinetics of a Single Dose of Oral Gatifloxacin in Beagle Dogs
下载PDF
导出
摘要 目的探讨加替沙星口服后在Beagle犬体内药代动力学。方法将18只Beagle犬分为3组,分别灌服34,17,8.5mg/kg加替沙星,于给药后0.5,1,2,4,6,8,12,24,36,48,60h取血,以高效液相色谱法测定血药浓度,用3P97程序分析。结果高、中、低剂量组动物吸收相半衰期(t1/2ka)分别为(0.82±0.96),(0.78±0.77),(1.33±0.43)h,消除相半衰期(t1/2ke)分别为(7.33±1.79),(6.32±3.28),(5.34±2.60)h,达峰时间(tmax)分别为(6.32±2.32),(3.95±2.18),(5.77±1.62)h,峰浓度(Cmax)分别为(6.31±2.66),(2.67±0.64),(0.64±0.30)mg/mL。药时曲线下面积(AUC0→60)分别为(110.86±43.76),(41.93±5.58),(8.58±2.70)μg·h/mL。结论加替沙星口服易吸收,血药浓度高,代谢慢,临床使用方便。 Objective To study the pharmacokinetics of a single dose of oral gatifloxacin capsules in Beagle dogs. Methods 18 Beagle dogs were divided into 34,17,8.5 mg/kg groups,single dose of 34,17,8.5 mg/kg of gatifloxacin was administrated. The blood samples were taken at 0. 5,1,2,4, 6,8,12,24,36,48,60 h after oral administration. The concentration of gatifloxacin in serum was determined by a HPLC method,pharmacokinetic parameters were calculated with pharmacokinetic program (3P97). Results The concentration- time curves of gati- floxacin fitted to one - compartment model, t1/2ke was (0.82 ± 0. 96), (0. 78 ± 0. 77), (1.33 ± 0. 43)h respectively, t1/2ke was (7.33 ± 1.79), (6. 32 ± 3.28), (5.34 ± 2.60) h respectively, tmax was (6.32 ± 2.32), (3.95 ± 2.18), (5.77 ± 1.62) h respectively, Cmax was (6.31 ± 2.66), (2.67 ± 0. 64), (0.64±0.30) mg/mL respectively, AUC0→60 was (110.86 ± 43.76), (41.93 ± 5.58), (8.58 ± 2. 70) μg· h/mL respectively. Conclusion The gatifloxacin was absorbed rapidly, and high in plasma, and metabolized slowly. The convenience is oral administration gatifloxacin in clinical practice.
作者 李绪春 朱红
出处 《中国药业》 CAS 2006年第10期6-7,共2页 China Pharmaceuticals
关键词 加替沙星 BEAGLE犬 药代动力学 高效液相色谱法 gatifloxacin Beagle dog pharmacokinetics HPLC
  • 相关文献

参考文献4

二级参考文献38

  • 1赵树清,王金生.新型氟喹诺酮抗菌剂——AM—1155[J].中国医药情报,1996,2(4):249-252. 被引量:4
  • 2[1]Hosaka M,Yaxue T, Fukuda H, Tomizawa H, et al.In vitro and in vivo antibacterial activities of AM-1 155, a new 6-fluoro-8-methoxy quinolone. Antimicrobial Agents Chemotherapy, 1992;36:2108~2117.
  • 3[2]Wakabayashi E, Mitsuhashi S. In vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methyoxy quinolone. Antimicrobial Agents Chemotherapy, 1994;38:594~601.
  • 4[3]Wise R, Brenwald NP, Andrews JM,et al. The activity of the methylpiperazinyl fluoroquinolone CG5501:A comparison with other fluoroquinolones fluoroquinolones. Antimicrobial Chemotherapy, 1997;39:447~452.
  • 5[4]National Committee for Clinical Laboratory Standards. 1998;18.
  • 6[5]Hosaka M,Kinoshita S, Toyama A,et al. Antibacterial Properties of AM-1155, a new 8-methoxy quinolone. Antimicrobial Chemotherapy, 1995; 36:293~301.
  • 7[6]Tanaka M,Takahashi K, Saika T, et al. Development of fluoroquinoloneresistance and mutations involving GyrA and ParC proteins among Neisseria gonorrhoeae in Japan. Urology, 1998; 159:2215~2219.
  • 8[7]Deguchi T, Yasuda M, Nakano M,ea al. Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GryA and ParC.Chemotherapy, 1997;43:239~244.
  • 9[8]Nakashima M,Uematsu T,Kosuge K, et al. Single and multiple-dose pharmacolinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. Antimicrobial Agents Chemotherapy,1995;39:2635~2640.
  • 10[1]Perry CM, Barman Balfour JA, Lamb HM. Gatifloxacin[J].Drugs, 1999;58(4):683-7

共引文献111

同被引文献21

引证文献4

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部